| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/01/2001 | WO2001007655A1 Antisense modulation of shp-2 expression |
| 02/01/2001 | WO2001007612A2 Receptors and associated proteins |
| 02/01/2001 | WO2001007477A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 02/01/2001 | WO2001007475A1 Novel peptides |
| 02/01/2001 | WO2001007471A2 Cell cycle and proliferation proteins |
| 02/01/2001 | WO2001007457A1 Antisense modulation of pten expression |
| 02/01/2001 | WO2001007440A1 Imidazoimidazoles and triazoles as anti-inflammatory agents |
| 02/01/2001 | WO2001007435A2 N-(indolcarbonyl-)piperazin derivatives als 5-ht2a-receptor ligands |
| 02/01/2001 | WO2001007424A1 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands |
| 02/01/2001 | WO2001007417A1 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 02/01/2001 | WO2001007409A1 Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| 02/01/2001 | WO2001007405A2 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 02/01/2001 | WO2001007078A1 Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases |
| 02/01/2001 | WO2001007074A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 02/01/2001 | WO2001007057A1 Treatment of angiogenesis dependent conditions with dextrin sulphate |
| 02/01/2001 | WO2001007036A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN |
| 02/01/2001 | WO2001006989A2 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 02/01/2001 | WO2001006984A2 Small molecules useful in the treatment of inflammatory disease |
| 02/01/2001 | WO2000054764A3 A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications |
| 02/01/2001 | WO2000049043A3 Human lipid-associated proteins |
| 02/01/2001 | WO2000047194A3 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| 02/01/2001 | WO2000043781A3 Growth differentiation factor inhibitors and uses therefor |
| 02/01/2001 | DE19935771A1 Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln New vitamin D derivatives with cyclic substructures in the side chains, to processes and intermediates for their preparation and to the use for the preparation of medicaments |
| 02/01/2001 | CA2696819A1 Ghrelin related peptides |
| 02/01/2001 | CA2396591A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 02/01/2001 | CA2383017A1 Imidazoimidazoles and triazoles as anti-inflammatory agents |
| 02/01/2001 | CA2380037A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 02/01/2001 | CA2379801A1 Receptors and associated proteins |
| 02/01/2001 | CA2379784A1 Cell cycle and proliferation proteins |
| 02/01/2001 | CA2379659A1 Antisense modulation of pten expression |
| 02/01/2001 | CA2378953A1 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 02/01/2001 | CA2378860A1 Bicyclic antagonists selective for the .alpha.v.beta.3 integrin |
| 02/01/2001 | CA2378845A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 02/01/2001 | CA2378776A1 Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of medicament for the treatment of glycolipid storage diseases |
| 02/01/2001 | CA2378395A1 Treatment of angiogenesis dependent conditions with dextrin sulphate |
| 02/01/2001 | CA2376465A1 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 01/31/2001 | EP1072680A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/31/2001 | EP1072609A2 Cytoprotective agents comprising prosaposin-related peptides |
| 01/31/2001 | EP1072255A2 Desferrioxamine oral delivery system |
| 01/31/2001 | EP1072198A1 Preparation especially for use as medicament and/or nutritional supplement |
| 01/31/2001 | EP1071781A1 B-cell growth factor related protein |
| 01/31/2001 | EP1071778A2 Srebp-2-deficient cell lines |
| 01/31/2001 | EP1071755A1 Human bile salt-stimulated lipase (bssl) obtainable from transgenic sheep |
| 01/31/2001 | EP1071708A1 Edg family gene, human h218 |
| 01/31/2001 | EP1071686A1 Novel heterocyclic compounds |
| 01/31/2001 | EP1071680A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| 01/31/2001 | EP1071679A1 Novel heterocyclic compounds |
| 01/31/2001 | EP1071666A1 Azacycloalkane derivatives, preparation and therapeutic application |
| 01/31/2001 | EP1071447A1 Treatment for diabetes |
| 01/31/2001 | EP1071439A1 Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
| 01/31/2001 | EP1071433A2 Pharmaceutical composition |
| 01/31/2001 | EP1071424A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph |
| 01/31/2001 | EP1071414A1 Compounds and methods for treating mitochondria-associated diseases |
| 01/31/2001 | EP1071403A1 Pharmaceutical composition containing a statin and aspirin |
| 01/31/2001 | EP1071326A1 Method of regulating appetite and metabolism |
| 01/31/2001 | EP0920528A4 Synthetic protein folding catalysis |
| 01/31/2001 | CN1282338A A DNA molecule encoding mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof |
| 01/31/2001 | CN1282325A Arylthiazolidinedione derivatives |
| 01/31/2001 | CN1282246A Rapidly soluble drug composition |
| 01/31/2001 | CN1282223A Fat blend |
| 01/31/2001 | CN1281716A Medicine for curing diabetic peripheral neuropathy |
| 01/31/2001 | CN1061241C Medicine for treating diabetes |
| 01/30/2001 | US6180787 Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides |
| 01/30/2001 | US6180680 Cardiovascular disorders |
| 01/30/2001 | US6180676 Guanylhydrazones and their use to treat inflammatory conditions |
| 01/30/2001 | US6180643 Antagonist of interleukins, tumor necrosis factor |
| 01/30/2001 | US6180618 Propanolamine derivatives linked to bile acids, processes for their preparation, pharmaceuticals comprising these compounds, and their use |
| 01/30/2001 | US6180403 Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression |
| 01/30/2001 | US6180384 Compounds |
| 01/30/2001 | US6180370 Preparing preferential antibodies; generating nucleotide sequences coding preferential antibodies, expressing nucleotide sequences in transformed cell and recovering preferential antibodies |
| 01/30/2001 | CA2313825A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/30/2001 | CA2191352C Quinoline derivatives as tachykinin nk3 receptor antagonists |
| 01/30/2001 | CA2148112C New pharmaeutical dosage form for transdermal administration |
| 01/30/2001 | CA2145640C Substituted pyrimidines for control of diabetic complications |
| 01/30/2001 | CA2011171C Biodegradable poly (phosphate esters) |
| 01/29/2001 | CA2314682A1 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 01/26/2001 | CA2314418A1 Incorporation of cholesterol lowering agents into confectionery dosage forms |
| 01/25/2001 | WO2001006261A2 Screening for therapeutic agents being scap antagonists |
| 01/25/2001 | WO2001006015A1 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 01/25/2001 | WO2001005983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | WO2001005974A2 The il-1l1 gene and polypeptide products |
| 01/25/2001 | WO2001005972A1 Compositions and methods for the treatment of immune related diseases |
| 01/25/2001 | WO2001005969A2 Electron transfer proteins |
| 01/25/2001 | WO2001005954A1 Antisense modulation of liver glycogen phosphorylase expression |
| 01/25/2001 | WO2001005947A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | WO2001005937A2 Conversion of a watson-crick dna to a hoogsteen-paired duplex |
| 01/25/2001 | WO2001005834A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | WO2001005794A2 Method for making debromohymenialdisine and analogs thereof |
| 01/25/2001 | WO2001005793A1 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION |
| 01/25/2001 | WO2001005790A1 New compounds |
| 01/25/2001 | WO2001005783A1 Bradykinin b1 receptor antagonists |
| 01/25/2001 | WO2001005780A1 Coumarone analogues |
| 01/25/2001 | WO2001005776A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 01/25/2001 | WO2001005772A1 Pyrazinones, compositions containing such compounds |
| 01/25/2001 | WO2001005762A2 Biphenyl derivatives, production thereof and use as mtp inhibitors |
| 01/25/2001 | WO2001005586A1 Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery |
| 01/25/2001 | WO2001005412A1 Cholesterol-lowering agents, secondary bile acid procuction inhibitors and foods and drinks |
| 01/25/2001 | WO2001005408A1 Fat-binding polymers, optionally combined with lipase inhibitors |
| 01/25/2001 | WO2001005397A1 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same |
| 01/25/2001 | WO2001005392A2 Method for treating chronic pain using mek inhibitors |